News Archives - Page 15 of 87

TuesdayFeb 13, 2024 2:35 pm

TinyGemsBreaks — Vision Marine Technologies Inc. (NASDAQ: VMAR) Names MarineMax Executive to Board

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry, announced that Anthony E. Cassella Jr., executive vice president finance and chief accounting officer at MarineMax Inc. (NYSE: HZO) has been appointed to its board of directors; Cassella will serve as an independent director. According to the announcement, the appointment reflects VMAR’s leading role in marine technology innovation and underscores its commitment to strong corporate governance; the company noted that the veteran’s background and industry knowledge “will bring incredible value to the next chapter of Vision Marine's mission to become the leading provider…

TuesdayFeb 13, 2024 2:09 pm

TinyGemsBreaks – GEMXX Corp. (GEMZ) Announces Groundbreaking Start for January Product Deliveries

GEMXX (OTC: GEMZ), a pioneering mine-to-market gold, gemstone and jewelry producer, today announced a stellar start to the year with impressive product deliveries worth $1,051,374 at retail for the month of January. According to the announcement, January’s deliveries mark an incredible 600% increase compared to the same period last year, highlighting GEMXX's strong growth trajectory and its effective business strategies. “Our January delivery results are a testament to the hard work and dedication of the GEMXX team,” said Jay Maull, CEO of GEMXX Corporation. “Our ability to achieve such significant deliveries is a clear indication of our competitive edge in…

FridayFeb 09, 2024 1:25 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process;…

ThursdayFeb 08, 2024 2:03 pm

TinyGemsBreaks — Diamond Lake Minerals Inc. (DLMI) CEO Talks Commitment to Regulation, Discusses Vision for Real Estate Tokenization

Diamond Lake Minerals (OTC: DLMI), a leading player in the digital asset landscape bridging the gap between traditional finance and decentralized finance, is featured in a recent interview released from Proactive. During the interview, Diamond Lake Minerals CEO Brian J. Esposito talks with Proactive host Steve Darling about the company’s distinctive approach to digital assets. During the interview, Esposito explained that Diamond Lake Minerals focuses on security token offerings (“STOs”) within a regulated environment, which is distinctive from unregulated cryptocurrencies and represents the company’s commitment to regulatory compliance and security. Esposito also noted that Diamond Lakes places a high priority on transparency…

WednesdayFeb 07, 2024 2:22 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreements and material transfer agreements with several academic research collaborators. The programs will be focused on studying TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA(R) (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The company noted that new indications being evaluated include ALK-positive lung cancer as well as additional undisclosed programs. The expanded programs comprise research being conducted…

TuesdayFeb 06, 2024 2:35 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Bollinger’s Receipt of IRS Approval for $40K Commercial EV Tax Credit

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that Bollinger Motors (“Bollinger”) has received IRS approval as a “qualified manufacturer” for clean vehicle credits under the Inflation Reduction Act of 2022 (the “IRA”). According to the announcement, the designation enables the Bollinger B4 chassis cab to qualify for the IRA’s new credit for qualified commercial clean vehicles, providing eligible purchasers a tax credit of up to $40,000 per vehicle. “Bollinger Motors is poised for growth and we’re ready to help electrify America’s fleets,” said Robert Bollinger, founder and CEO of Bollinger Motors. “These tax credits are…

TuesdayFeb 06, 2024 12:23 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb. 26, will include an overview of the company's gene therapies for cancer and diabetes; Confer will also be available for in-person, one-on-one meetings with investors through the conference platform. To view the full press release,…

TuesdayFeb 06, 2024 12:09 pm

TinyGemsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”). Etherington and Darling discussed the trial, which involved gathering almost three years of research and information from participants with stable relapsing MS. Darling explained…

MondayFeb 05, 2024 1:00 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Reports on Production and Deliveries, Moves Forward with Production Line Installation

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting “great strides” with the production and deliveries of its Class 1 and Class 3 commercial EVs. In addition, the company is reporting that its subsidiary, Mullen Advanced Energy LLC, "), is moving forward with the installation of its battery-pack production line at its new 122,000-square-foot, high-energy facility in Fullerton, California. The company announced the new facility in November 2023; the new facility is dedicated to producing next-generation, American-made EV battery components, modules and packs. “We are steadfastly focused on production, production, production,” said Mullen Automotive CEO and chair…

MondayFeb 05, 2024 12:42 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca's Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2 clinical trial, the Accliam-1 trial has completed its phase 1 component and is moving on to phase 2. The company anticipates enrolling an estimated 66 patients in phase 2a, with one-half of the study participants…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News